WHEN A BIOTECH SAYS NO TO $30B PAY ATTENTION — BUYOUT TARGET
By Nigam Arora
Buyout Talks
Revolution Medicines (RVMD) was in talks to be acquired by Merck (MRK). The deal was valued around $30B. Apparently, Revolution Medicines wants a higher offer than Merck is willing to extend at this time.
In The Arora Report analysis, this indicates Revolution Medicines has enough confidence in its drug that it is willing to forego a great offer. Revolution Medicines is developing drugs that block a driver of cancer in pancreatic, lung, and colon cancer.
Buyout Target
Revolution Medicines still remains a buyout target.
Zones
The buy zone is $*** (To see the locked content, please take a 30 day free trial)- $*** to scale in.… Please click here or the title below to read more.
January 27, 2026